Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00935246 |
Recruitment Status : Unknown
Verified December 2015 by Doh Kwan Kim, Samsung Medical Center.
Recruitment status was: Active, not recruiting
First Posted : July 8, 2009
Last Update Posted : December 31, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Depression Continuous Antidepressant Abuse Adverse Reaction to Drug | Drug: Escitalopram | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 202 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning |
Study Start Date : | December 2008 |
Actual Primary Completion Date : | October 2011 |
Estimated Study Completion Date : | December 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Antidepressant treated group
Antidepressant treated group: depressed patients treated with Escitalopram
|
Drug: Escitalopram
Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose
Other Name: Escitalopram : Lexapro |
No Intervention: other antidepressant treated group
other Antidepressant treated group: depressed patients treated with other antidepressant without escitalopram
|
- antidepressant response at 2,4,6,8 weeks A/E monitoring at 1,2,4,6,8 weeks [ Time Frame: 8 weeks ]
- biological value at 0 week and 8 weeks [ Time Frame: 8 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years to 89 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Eligible patients were enrolled in the clinical trials program of hte Samsung Medical Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the Korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, Fourth edition.
- interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians
Exclusion Criteria:
- received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks
- potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00935246
Korea, Republic of | |
Samsung Medical Center | |
Kangnam, Seoul, Korea, Republic of, 135-710 |
Principal Investigator: | Doh Kwan Kim, PhD, M.D. | Samsung Medical Center |
Responsible Party: | Doh Kwan Kim, M.D., Ph.D., Samsung Medical Center |
ClinicalTrials.gov Identifier: | NCT00935246 |
Other Study ID Numbers: |
2008-12-042 |
First Posted: | July 8, 2009 Key Record Dates |
Last Update Posted: | December 31, 2015 |
Last Verified: | December 2015 |
Genomic devices Prediction of Escitalopram Response Depressed Patients |
Dexetimide Citalopram Drug-Related Side Effects and Adverse Reactions Chemically-Induced Disorders Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Serotonin Agents Physiological Effects of Drugs |
Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Antiparkinson Agents Anti-Dyskinesia Agents Parasympatholytics Autonomic Agents Peripheral Nervous System Agents Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents |